You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓(09939.HK)急漲22%成交增 新冠藥臨床試驗完成中國首例入組及給藥
阿思達克 02-14 11:56
開拓藥業(09939.HK)治療新冠藥臨床試驗完成中國首例入組及給藥,該股今早重越20天線(10.32元),最高見13.4元,現報12.16元,急漲22%,成交急增至1,895萬股。 開拓公布,上周四(10日)普克魯胺治療輕中症新冠患者全球多中心III期臨床試驗已在深圳市第三人民醫院完成中國首例受試者入組及給藥。此外,普克魯胺針對重症住院新冠患者的臨床試驗已在美國、烏克蘭、菲律賓全面啟動患者入組,目前正在中國臨床中心進行患者入組前的篩選。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account